Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma

被引：15
|
作者：
Lian, Bin
Cui, Chuanliang
Song, Xin
Zhang, Xiaoshi
Wu, Di
Si, Lu
Chi, Zhihong
Sheng, Xinan
Kong, Yan
Mao, Li Li
Zhou, Li
Wang, Xuan
Tang, Bixia
Yan, Xieqiao
Li, Siming
Li, Dan
Dai, Jie
Bai, Xue
Li, CaiLi
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[3] Jilin Univ, Hosp 1, Jilin, Jilin, Peoples R China
[4] Beijing Canc Hosp, Beijing, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Collaborat Innovat Ctr Canc Med, Dept Renal Canc & Melanoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
[6] Peking Univ Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9589
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
    Lian, Bin
    Si, Lu
    Cui, Chuanliang
    Chi, Zhihong
    Sheng, Xinan
    Mao, Lili
    Li, Siming
    Kong, Yan
    Tang, Bixia
    Guo, Jun
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4488 - 4498
  • [2] Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial.
    Lian, Bin
    Cui, Chuanliang
    Si, Lu
    Yang, Yue
    Wu, Di
    Li, Ke
    Wang, Xuan
    Chi, Zhihong
    Sheng, Xinan
    Mao, Lili
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Bai, Xue
    Zhou, Li
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial.
    Cui, Chuanliang
    Lian, Bin
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Kong, Yan
    Wang, Xuan
    Tian, Hui
    Mao, Lili
    Bai, Xue
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Toripalimab (anti-PD-1) versus high-dose interferon-a2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
    Lian, B.
    Si, L.
    Chi, Z. H.
    Sheng, X. N.
    Kong, Y.
    Wang, X.
    Tian, H.
    Li, K.
    Mao, L. L.
    Bai, X.
    Tang, B. X.
    Yan, X. Q.
    Li, S. M.
    Zhou, L.
    Dai, J.
    Tang, X. W.
    Ran, F. W.
    Yao, S.
    Guo, J.
    Cui, C. L.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (10) : 1061 - 1070
  • [5] Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma
    Lian, Bin
    Mao, Li Li
    Cui, Chuan Liang
    Chi, Zhi Hong
    Si, Lu
    Sheng, Xi Nan
    Li, Si Ming
    Tang, Bi Xia
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.
    Lian, Bin
    Tian, Hui
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Wang, Xuan
    Mao, Lili
    Bai, Xue
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Wei, Xiaoting
    Li, Juan
    Li, Caili
    Cui, Chuanliang
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma
    Gogas, H.
    Dafni, U.
    Bafaloukos, D.
    Polyzos, A.
    Kokkalis, G.
    Kalofonos, H. P.
    Fountzilas, G.
    Skarlos, D.
    Tsoutsos, D.
    Pectasides, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
    Pectasides, Dimitrios
    Dafni, Urania
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis
    Polyzos, Aristidis
    Tsoutsos, Dimosthenis
    Kalofonos, Haralambos
    Fountzilas, George
    Panagiotou, Petros
    Kokkalis, George
    Papadopoulos, Othon
    Castana, Ourania
    Papadopoulos, Stefanos
    Stavrinidis, Elias
    Vourli, Georgia
    Ioannovich, John
    Gogas, Helen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
  • [9] SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.
    Grossmann, Kenneth F.
    Othus, Megan
    Tarhini, Ahmad A.
    Patel, Sapna Pradyuman
    Moon, James
    Sondak, Vernon K.
    Kirkwood, John M.
    Ribas, Antoni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Feasibility of high-dose interferon-α2b adjuvant therapy for high-risk resected cutaneous melanoma
    Muggiano, A
    Mulas, C
    Fiori, B
    Liciardi, G
    Pintus, M
    Tanca, L
    Tedde, A
    Turno, R
    Desogus, A
    [J]. MELANOMA RESEARCH, 2004, 14 (02) : S1 - S7
12345